APA (7th ed.) Citation

N, Y., O, S., & A, S. (2026). Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer. Naunyn-Schmiedeberg's archives of pharmacology, 399(10), 15163. https://doi.org/10.1007/s00210-026-05250-8

Chicago Style (17th ed.) Citation

N, Younes, Sadek O, and Sultan A. "Co-treatment of Colchicine and Rosiglitazone Synergistically Inhibits Cytokine-driven Inflammation and Modulates the Related Hsa-miRNA26a-5p, Hsa-miRNA21-5p, and STAT3 Expression in Non-small Cell Lung Cancer." Naunyn-Schmiedeberg's Archives of Pharmacology 399, no. 10 (2026): 15163. https://doi.org/10.1007/s00210-026-05250-8.

MLA (9th ed.) Citation

N, Younes, et al. "Co-treatment of Colchicine and Rosiglitazone Synergistically Inhibits Cytokine-driven Inflammation and Modulates the Related Hsa-miRNA26a-5p, Hsa-miRNA21-5p, and STAT3 Expression in Non-small Cell Lung Cancer." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 399, no. 10, 2026, p. 15163, https://doi.org/10.1007/s00210-026-05250-8.